Fierce Pharma October 6, 2023
While the White House recently touted the FDA’s efforts to mitigate the ongoing chemotherapy shortage in the U.S., a recent survey by the National Comprehensive Cancer Network (NCCN) shows that many treatment centers do not have enough supply of key medicines.
NCCN surveyed 29 of its member institutions throughout the month of September and found that 72% of centers are still experiencing a carboplatin shortage, while 59% are short on cisplatin.
The report is a follow-up to a June survey evaluating supply levels of the key platinum-based chemotherapies carboplatin and cisplatin. The June survey showed that 93% of centers were experiencing a carboplatin shortage, while 70% were low on cisplatin.
“It is extremely concerning that...
Today's Sponsors
Today's Sponsor